Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cell Cure Neurosciences Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners and 2 distinct art units. This indicates that each of the company's active applications is being reviewed by a different official in a different administrative division of the patent office.
LANKFORD JR, LEON B is the busiest examiner for the company, with 1 pending office action. With 2 distinct examiners and 2 distinct art units involved, there is no concentration in the current prosecution. Practitioners must navigate two separate examination environments within the Biotechnology & Pharmaceuticals sector, which requires tailoring strategies to the specific preferences of each examiner and the procedural standards of each distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.0% | +31.6% |
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18662758 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | LANKFORD JR, LEON B | — |
| 18424000 | EXPANSION OF RETINAL PIGMENT EPITHELIUM CELLS | BARRON, SEAN C | — |
| 17883263 | ASSESSING RETINAL PIGMENT EPITHELIAL CELL POPULATIONS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1653 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18662758 | RPE CELL POPULATIONS AND METHODS OF GENERATING SAME | LANKFORD JR, LEON B | 1657 | §112 | Non-Final OA | — | Pending | May 13, 2024 |
| 18424000 | EXPANSION OF RETINAL PIGMENT EPITHELIUM CELLS | BARRON, SEAN C | 1653 | §102§103§112DP | Non-Final OA | — | Pending | Jan 26, 2024 |
| 17883263 | ASSESSING RETINAL PIGMENT EPITHELIAL CELL POPULATIONS | NOBLE, MARCIA STEPHENS | 1632 | §103 | Non-Final OA | — | Pending | Aug 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial